Pune, India -- (SBWire) -- 06/22/2018 --Market Scenario

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world.  Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.

Intended Audience

Pharmaceutical Companies

Medical Devices Companies

Research and Development (R&D) Companies

Market Research and Consulting Service Providers

Potential Investors

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/633

Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Furthermore, increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the market growth.

From the few last decades, the government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.

Ageing, decreases the immunity of the body and increases the probability of diseases. According to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia likely to help the growth of the market over the forecast period.

On the other hand, the presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the market growth over the review period.  

The Asia gastrointestinal drugs market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.

Check for Report Discount @ https://www.marketresearchfuture.com/check-discount/633

Segmentation                                                                                                                                      

The Asia gastrointestinal drugs market is segmented on the basis of drug class and type of disease.

On the basis of drug class, it is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.

On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.

Key Findings

The Asia gastrointestinal drugs market is expected to reach USD 20,772.4 million by 2023 at a CAGR of 6.1%

Acid neutralizers segment accounted for the largest market share with 33.3% of the Asia gastrointestinal drug market, by drug types in 2016

In 2016, Esophagus diseases segment accounted for the major share of the market as it was the most widely occurring GI disease. The Asia esophagus diseases market by type of diseases is expected to reach USD 7,427.6 million by 2023, growing at a CAGR of 6.32% from 2017 to 2023

India is expected to be the fastest growing market at a CAGR of 6.60% during the forecast period 

TABLE OF CONTENTS

1  REPORT PROLOGUE

2   INTRODUCTION

2.1 Scope Of Study 14

2.2 Research Objective 14

2.3 Assumptions & Limitations 14

2.3.1 Assumptions 14

2.3.2 Limitations 14

2.4 Market Structure 15

3  RESEARCH METHODOLOGY

3.1 Primary Research 18

3.2 Secondary Research 18

3.3 Market Size Estimation 18

3.3.1 Market Share Analysis 19

3.4 Market Pricing Approach 20

4  MARKET DYNAMICS

4.1 Introduction 21

4.2 Drivers 22

4.2.1 Increasing Prevalence Of Gastrointestinal Diseases 22

4.2.2 Increasing Investments And Funding In The Field Of Life Science Research 22

4.2.3 Increasing Awareness Among The People 23 

Key Players                                                                                                         

Some of the key players in this market are Abbott, Allergan Plc, AstraZeneca, Eli lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals, and others.

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/633

 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.